Phrontline Biopharma
Wednesday, June 05, 2024
Oncology
Company Presentation Theater 1
Phrontline Biopharma is dedicated to develop novel formats of ADCs for unmet medical needs in oncology. Our company specializes in selecting and optimizing dual targeting in ADC. To improve drug resistance, Phrontline has developed dual linker payload platforms to extend drug response based on several decades of clinical experience of combo chemotherapy. Convicted to improve patient’s health and guided by Science, Phrontline is dedicated to being a premier international biopharma specialized in ADC drug development.
.jpg)
Company Website:
http://PhrontlineBio.com
Lead Product in Development:
TJ101(a bispecific ADC) in IND enabling study
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Two, TJ101 and TJ102
Company HQ City
shanghai
Company HQ State
Shanghai
Company HQ Country
China
CEO/Top Company Official
Zhaoyuan Chen
Development Phase of Primary Product
Pre-Clinical
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())